Damiënne Marcus

Ms. Damiënne Marcus


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2020 in British Journal of Radiology
Verified
Journal Article
Closed access
WRWilliam Rogers
William Rogers
SSSithin Thulasi Seetha
Sithin Thulasi Seetha
TRTurkey Refaee
Turkey Refaee
RLRelinde I. Y. Lieverse
Relinde I. Y. Lieverse
Renée GranzierRenée Granzier
Renée Granzier
Philippe LambinPhilippe Lambin
Philippe Lambin
Historically, medical imaging has been a qualitative or semi-quantitative modality. It is difficult to quantify what can be seen in an image, and to turn it into valuable predictive outcomes. As a result of advances in both computational hardware and machine learning algorithms, computers are making great strides in obtaining quantitative information from imaging and correlating it with outcomes. Radiomics, in its two forms “handcrafted and deep,” is an emerging field that translates medical images into quantitative data to yield biological information and enable radiologic phenotypic profiling for diagnosis, theragnosis, decision support, and monitoring. Handcrafted radiomics is a multistage process in which features based on shape, pixel intensities, and texture are extracted from radiographs. Within this review, we describe the steps: starting with quantitative imaging data, how it can be extracted, how to correlate it with clinical and biological outcomes, resulting in models that can be used to make predictions, such as survival, or for detection and classification used in diagnostics. The application of deep learning, the second arm of radiomics, and its place in the radiomics workflow is discussed, along with its advantages and disadvantages. To better illustrate the technologies being used, we provide real-world clinical applications of radiomics in oncology, showcasing research on the applications of radiomics, as well as covering its limitations and its future direction.

1 August 2017 in British Journal of Radiology
Verified
Journal Article
Open access
ELEvert J Van Limbergen
Evert J Van Limbergen
Dirk De RuysscherDirk De Ruysscher
Dirk De Ruysscher
VPVeronica Olivo Pimentel
Veronica Olivo Pimentel
DMDamiënne Marcus
Damiënne Marcus
MBMaaike Berbee
Maaike Berbee
PLPhilippe Lambin
Philippe Lambin
The advent of immunotherapy is currently revolutionizing the field of oncology, where different drugs are used to stimulate different steps in a failing cancer immune response chain. This review gives a basic overview of the immune response against cancer, as well as the historical and current evidence on the interaction of radiotherapy with the immune system and the different forms of immunotherapy. Furthermore the review elaborates on the many open questions on how to exploit this interaction to the full extent in clinical practice.

23 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
DMDamiënne Marcus
Damiënne Marcus
RLRelinde I. Y. Lieverse
Relinde I. Y. Lieverse
CKCarmen Klein
Carmen Klein
AAAmir Abdollahi
Amir Abdollahi
Philippe LambinPhilippe Lambin
Philippe Lambin
AYAla Yaromina
Ala Yaromina
Radiotherapy (RT) has been shown to interfere with inflammatory signals and to enhance tumor immunogenicity via, e.g., immunogenic cell death, thereby potentially augmenting the therapeutic efficacy of immunotherapy. Conventional RT consists predominantly of high energy photon beams. Hypofractionated RT regimens administered, e.g., by stereotactic body radiation therapy (SBRT), are increasingly investigated in combination with cancer immunotherapy within clinical trials. Despite intensive preclinical studies, the optimal dose per fraction and dose schemes for elaboration of RT induced immunogenic potential remain inconclusive. Compared to the scenario of combined immune checkpoint inhibition (ICI) and RT, multimodal therapies utilizing other immunotherapy principles such as adoptive transfer of immune cells, vaccination strategies, targeted immune-cytokines and agonists are underrepresented in both preclinical and clinical settings. Despite the clinical success of ICI and RT combination, e.g., prolonging overall survival in locally advanced lung cancer, curative outcomes are still not achieved for most cancer entities studied. Charged particle RT (PRT) has gained interest as it may enhance tumor immunogenicity compared to conventional RT due to its unique biological and physical properties. However, whether PRT in combination with immune therapy will elicit superior antitumor effects both locally and systemically needs to be further investigated. In this review, the immunological effects of RT in the tumor microenvironment are summarized to understand their implications for immunotherapy combinations. Attention will be given to the various immunotherapeutic interventions that have been co-administered with RT so far. Furthermore, the theoretical basis and first evidences supporting a favorable immunogenicity profile of PRT will be examined.

22 May 2020 in Cancers
Verified
Journal Article
Open access
PDF file
SSSebastian Sanduleanu
Sebastian Sanduleanu
AWAlexander van der Wiel
Alexander van der Wiel
RLRelinde I.Y. Lieverse
Relinde I.Y. Lieverse
DMDamiënne Marcus
Damiënne Marcus
AIAbdalla Ibrahim
Abdalla Ibrahim
Philippe LambinPhilippe Lambin
Philippe Lambin
Hypoxia—a common feature of the majority of solid tumors—is a negative prognostic factor, as it is associated with invasion, metastasis and therapy resistance. To date, a variety of methods are available for the assessment of tumor hypoxia, including the use of positron emission tomography (PET). A plethora of hypoxia PET tracers, each with its own strengths and limitations, has been developed and successfully validated, thereby providing useful prognostic or predictive information. The current review focusses on [18F]-HX4, a promising next-generation hypoxia PET tracer. After a brief history of its development, we discuss and compare its characteristics with other hypoxia PET tracers and provide an update on its progression into the clinic. Lastly, we address the potential applications of assessing tumor hypoxia using [18F]-HX4, with a focus on improving patient-tailored therapies.

15 June 2020 in Cancers
Verified
Journal Article
Open access
PDF file
AMAlexandra Mowday
Alexandra Mowday
NLNatasja G. Lieuwes
Natasja G. Lieuwes
RBRianne Biemans
Rianne Biemans
DMDamiënne Marcus
Damiënne Marcus
BRBehzad Rezaeifar
Behzad Rezaeifar
Ludwig DuboisLudwig Dubois
Ludwig Dubois
Glioblastoma multiforme (GBM) is a common and aggressive malignant brain cancer with a mean survival time of approximately 15 months after initial diagnosis. Currently, the standard-of-care (SOC) treatment for this disease consists of radiotherapy (RT) with concomitant and adjuvant temozolomide (TMZ). We sought to develop an orthotopic preclinical model of GBM and to optimize a protocol for non-invasive monitoring of tumor growth, allowing for determination of the efficacy of SOC therapy using a targeted RT strategy combined with TMZ. A strong correlation (r = 0.80) was observed between contrast-enhanced (CE)-CT-based volume quantification and bioluminescent (BLI)-integrated image intensity when monitoring tumor growth, allowing for BLI imaging as a substitute for CE-CT. An optimized parallel-opposed single-angle RT beam plan delivered on average 96% of the expected RT dose (20, 30 or 60 Gy) to the tumor. Normal tissue on the ipsilateral and contralateral sides of the brain were spared 84% and 99% of the expected dose, respectively. An increase in median survival time was demonstrated for all SOC regimens compared to untreated controls (average 5.2 days, p < 0.05), but treatment was not curative, suggesting the need for novel treatment options to increase therapeutic efficacy.